The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Timing matters: automatic rebalancing should occur as your allocations drift beyond set thresholds.
18,157 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Bond markets show renewed stress, with yields rising and liquidity thinning. Analysts say a familiar pattern is reeme...
Oil climbs again, lifting energy costs and weighing on equities. The S&P 500, SPY, and the Dow all move lower as mark...
Britain’s bond panic currently reshapes how households view cash, debt, and even crypto, as gilt volatility and infla...
BTS returns with a high-profile comeback tour after completing military service, signaling a push to reclaim global p...
Bitcoin hovers near a critical zone as traders weigh whether a floor is forming or a deeper pullback lies ahead. ETF ...
A Melius analyst warns that Microsoft's Copilot leadership reshuffle may signal deeper misalignment between AI ambiti...
Capital One’s stock sits near $184 after a wave of acquisitions and an earnings miss. Here’s what Wall Street expects...
Bitcoin is gaining traction as a potential safe haven as geopolitical tensions heighten market nerves and gold funds ...
Insmed disclosed that Japan now hosts more MAC lung disease patients than the United States, a development that could...
Vail Resorts is signaling a strategic pivot away from the iconic $1,000 Epic Pass as season results lag and weather c...
Analysts project XRP could climb to multi-dollar levels by 2030, but the path hinges on regulatory outcomes and Rippl...